Remarkable regression of a giant cell tumor of the cervical spine treated conservatively with denosumab: A case report  by Nakazawa, Toshiyuki et al.
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INTRODUCTION:  Wide  resection  of  giant  cell  tumors  at the  cervical  spine  is  sometimes  extremely  chal-
lenging,  especially  in  cases  where  tumors  extend  into  the  nearby  tissues,  such  as vertebral  arteries,  the
spinal  cord,  or  spinal  nerve  roots.  Denosumab,  a human  monoclonal  antibody  that  binds  the  receptor
activator  of  nuclear  factor - ligand,  is  reported  to be  effective  for  decreasing  resorption  of  giant  cell
tumor  of  the bone,  but the  detailed  progress  of giant  cell  tumors  in  the cervical  spine  extending  into  the
nearby  tissues  after  such  treatment  has  not  been  reported.
PRESENTATION  OF  CASE:  A  41-year-old  man  presented  with  neck  pain.  Computed  tomography-guided
needle  biopsy  showed  numerous  giant  cells  with  a  large  vesicular  nucleus,  consistent  with  a  giant  cell
tumor.  Because  of the  extension  of  the  tumor  with  involvement  of  the vertebral  artery  and  surround-
ing  tissues,  denosumab  (120  mg)  was  administered  subcutaneously  once  per month  for  24 months.
Six  months  after  denosumab  treatment,  follow-up  computed  tomography  revealed  a dramatic  regres-
sion  and  osteosclerosis  of the tumor.  Two  years  after  starting  denosumab  treatment,  positron  emission
tomography  showed  no tumor  recurrence.
DISCUSSION:  Although  the  tumor  was  extended  with  involvement  of  the  surrounding  tissues  and  surgery
following  denosumab  treatment  was  not  performed,  at 24 months  since  initiation  of denosumab  treat-
ment  we  conﬁrmed  complete  regression  radiographically.
CONCLUSIONS:  Denosumab  may  be used  as an adjuvant  by which  to avoid  or reduce  the  risks  and  mor-
bidity  of  surgical  treatment  in  patients  with  spinal  giant  cell tumors  extending  into  nearby  tissues.
© 2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Giant cell tumor (GCT) of the bone is a benign primary bone
eoplasm, which presents a locally aggressive behavior causing
xtensive lytic lesions [1]. GCT occurring in the vertebrae report-
dly accounts for 2.7%–6.5% of GCTs of the bone [2]. Although total
esection at an early stage remains the best treatment strategy
ith a low recurrence rate [3,4], the surgical treatment of GCT
f the spine is sometimes challenging or unsalvageable because
f the complicated surrounding anatomy. Recently, denosumab
reatment had been explored. Denosumab is a human monoclonal
ntibody that binds the receptor activator of nuclear factor kappa-
igand (RANKL), preventing activation of its receptor (RANK) on the
urface of giant cells, osteoclast precursors, and osteoclasts. Preven-
ion of the RANK–RANKL interaction inhibits osteoclast formation,
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function, and survival, thereby decreasing resorption in GCT of the
bone [5]. Herein, we  report the case of a patient with GCT  of the
cervical spine treated with denosumab, which showed remarkable
regression without surgery.
2. Case presentation
A 41-year-old Japanese man  presented at our hospital with
cervical pain for one month. His cervical pain began without
any traumatic episode and was  continuous regardless of his neck
motion. Neurological examination was normal. Plain lateral cervi-
cal radiographs showed a collapse of the C5 vertebral body, whose
posterior wall protruded into the spinal canal (Fig. 1). Computed
tomography (CT) revealed an expansive osteolytic mass lesion
on the C5 vertebral body extending into the bilateral transverse
foramen (Fig. 2A). 18F-Fluorodeoxyglucose (ﬂudeoxyglucose F 18)
positron emission tomography (FDG-PET)/CT showed signiﬁcant
uptake at the C5 vertebral body (Fig. 3A). A CT-guided needle biopsy
of the C5 vertebra was  performed via the right posterior lamina.
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Plain lateral cervical radiographs before denosumab treatment.
Plain lateral cervical radiographs showing a collapse of the C5 vertebral body, whose
posterior wall protruded into the spinal canal.
Fig. 2. Axial CT during denosumab treatment.
Axial CT of the C5 vertebra. A. Before denosumab treatment; B, 6 months; C, 12 months; D
osteosclerosis were noted on the lytic areas, which were seen before denosumab treatmePEN  ACCESS
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The tumor was osteolytic and friable, and diagnosed histologically
as a GCT of the bone (Fig. 4). Because of the extension of the tumor
with involvement of the vertebral artery and surrounding tissues,
denosumab treatment was planned. Subcutaneous administration
of 120 mg  of denosumab (Ranmark, Daiichi Sankyo Co., Tokyo,
Japan) was started, and continued once per month. His neck pain
disappeared completely within three months after administration,
without any adverse events. CT showed dramatic regression and
surrounding sclerosis of the tumor six months after denosumab
administration (Fig. 2B). We  decided to continue the denosumab
treatment and to postpone surgical resection. During follow-up,
gradual regression and surrounding osteosclerosis were noted on
the previously lytic areas every 6 months for 2 years (Fig. 2A–D),
without any adverse events. Following FDG-PET/CT showed no
obvious uptake (Fig. 3B). Because of the markedly favorable course
of this patient, we  decided that further surgical resection would not
be necessary. The patient is still under clinical surveillance and has
remained asymptomatic for 2 years since denosumab treatment
started.
3. Discussion
Denosumab is a fully human monoclonal antibody with high
afﬁnity for RANKL and therapeutic potential for the treatment of
GCT of the bone [6]. In prospective randomized trials, the efﬁcacy
of denosumab for GCT has been proven, and it has been registered
for treatment of GCT with the United States Food and Drug Admin-
, 24 months after treatment with denosumab. Gradual regression and surrounding
nt.
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Fig. 3. Axial 18F-FDG PET/CT of the C5 vertebra.
A. Before denosumab treatment, an obviously lobulated FDG uptake was noted; B, 2 year
Fig. 4. Histology of the biopsy specimen before denosumab treatment.
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cumerous giant cells with a large vesicular nucleus exist, which is consistent with
CT. Scale bar = 100 m.
stration (U.S. FDA), the European Medicines Agency (EMA), and the
harmaceuticals and Medical Devices Agency (PMDA) in Japan. A
revious study evaluated the efﬁcacy of denosumab in 282 patients
ith GCT of the bone, and found 96% of surgically unsalvageable
atients had no progression after a median follow-up of 13 months
7]. Tse et al. classiﬁed the extent of GCT of the bone into 3 stages
ased on plain radiographs: stage I, tumors remain conﬁned to a
mall area within the bone; stage II, tumors expand to the cortex;
nd stage III, tumors breach the cortex and may  extend into the
earby tissues [8]. They reported 7 cases with a recurrence of GCT
n 44 patients with surgical resection, and all 7 cases with recur-
ence were in stage III, indicating that if the tumor extends into
he nearby tissues it is easily recurrent. Although the present case
as in stage III, its remarkable regression was sustained without
ocal recurrence for at least 2 years. In the present case, we  did
ot use subsequent adjuvant therapy or radiotherapy. van der Hei-
den et al. reported that additional radiotherapy should be limited
o unresectable, residual, or recurrent cases in which treatment
ith denosumab is not indicated [9]. Whether additional adju-
ant therapy or radiotherapy is meaningful for the patients treated
onservatively with denosumab warrants further evaluation. Gold-s after denosumab treatment, no uptake was seen.
schlager et al. reported 4 cases of GCT of the spine with preoperative
denosumab treatment followed by surgical resection, and reported
an average 6 months’ treatment with denosumab reduced tumor
size from 10% to 40% before surgery [10]. There are a few cases
of spinal GCT with almost complete regression with denosumab
after arthrodesis without resection [11]. However, to our knowl-
edge, this is the ﬁrst report of a case with surgically unsalvageable
GCT at the cervical spine treated with denosumab alone for up to
two years, thus avoiding the risks and morbidity of the surgery. A
complete surgical resection of the tumor is recognized as the ulti-
mate goal when treating a GCT of the spine because when resection
is done properly, it can result in oncological control, the risk of local
recurrence is mitigated, and it can obviate comorbidities associated
with reoperation [12–14]. Although, there reported that no giant
cell or stromal cell was  detected pathologically in resected ver-
tebra after preoperative denosumab treatment for 6 months [15].
Nevertheless, the duration of denosumab treatment of these cases
without resection remains controversial. Recently, a high-grade
sarcoma was  reported as developing in a case of tibial GCT during
denosumab treatment [16]. It is still unclear whether malignant
transformation is caused by denosumab treatment itself. Addition-
ally, the clinical course after completion of denosumab treatment
with adequate duration is uncertain. Further study of spinal GCT
with denosumab treatment with larger numbers of patients and a
longer follow up is warranted.
4. Conclusion
Denosumab can be used as an adjuvant therapy, by which to
avoid or reduce the risks and morbidity of surgical treatment in
patients with spinal GCTs extending into the nearby tissues, con-
sidering the adequate duration, safety, and lack of adverse events
of this treatment, even though further evidence with more patients
and a longer follow-up is warranted.Conﬂicts of interest
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